BioXcel Therapeutics (BTAI) Research & Development (2017 - 2026)

BioXcel Therapeutics' Research & Development history runs 10 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• In Q1 2026, Research & Development fell 35.11% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $28.7 million (up 21.47% YoY), while the FY2025 annual figure was $30.3 million, down 0.6% from the prior year.
• Research & Development was $3.0 million for Q1 2026 at BioXcel Therapeutics, down from $6.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $32.5 million in Q4 2022 to a low of $3.0 million in Q1 2026.
• Historically, Research & Development has averaged $14.1 million across 5 years, with a median of $10.3 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Research & Development surged 159.15% in 2022, then sank 74.0% in 2024.
• A 5-year view of Research & Development shows it stood at $32.5 million in 2022, then tumbled by 69.4% to $9.9 million in 2023, then sank by 40.6% to $5.9 million in 2024, then increased by 13.56% to $6.7 million in 2025, then slumped by 55.9% to $3.0 million in 2026.
• The last three Research & Development figures came in at $3.0 million (Q1 2026), $6.7 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.